Our Niche

MATRIX45 occupies a special niche in the healthcare consulting and science sector.  We focus on building the evidence bases needed for informed strategic planning and decision-making.  Our emphasis is on providing value-added services - putting our brains to work to the knowledge benefit of our clients.

Core to our work is the recognition, by clients and by us, that an evidence-based approach is key to examining issues and developing solutions: either by generating new data, using existing data, or synthesizing various data or knowledge sources.

Top of Page

Our Clients

Our home page outlines our key client groups and some of the strategic areas in which we can help.

On the corporate end, MATRIX45 serves pharmaceutical and biotechnology companies, manufacturers of diagnostic and medical devices, and contract research organizations (CROs).  On the not-for-profit end, we work with research groups, universities, and healthcare providers.

Each of these client groups faces its own challenges and opportunities in evidence-based development and decision-making.  The issues are different from one sector to another.  However, these sectors' shared commitment to evidence enables MATRIX45 to apply the core tools of evidence-based practice and management while also custom-tailoring services and solutions to specific determinants, processes, and contexts of each of our client sectors.

How do we see our various consulting and development/support services benefiting our clients?

In addition, we recently added healthcare litigation support to our services.  This extends our reach for evidence-based expertise to those representing plaintiffs or defendants, as well as risk managers.

Top of Page   Top of Section

At MATRIX45, our  mission is to serve with creativity, expertise, dedication, and responsiveness the various healthcare sectors that develop or use scientific evidence for the purpose of clinical progress or strategic advantage.

At MATRIX45 you will find an unrelenting drive for quality and integrity.  To this end, we have adopted client- and project-centric methods of planning, implementing, and evaluating our work.  We focus on analyzing and solving the business issues of our clients.  We want to be more than vendors of services.  Instead, we strive to forge partnerships that address the business issues at hand - but also embed knowledge and expertise in our client's organizations.  To us, quality is more than client satisfaction.  Our goal is to exceed our clients' expectations in terms of value, innovation, responsiveness, and change.  We believe in the concept of learning organizations, yours and ours: knowledgeable, experienced, inventive - nimble, agile, innovative - intuitive, inquisitive, evidence-based.  We think out-of-the-box and aim to broaden and extend horizons, but pragmatically so.  We are accountable to our clients: for the work done, for the work's relevance, and for the value delivered.  We use service-based pricing, not level-based pricing.  Our accounting is transparent.

A word about confidentiality ... At MATRIX45, confidentiality is both a principle and a method.  We adhere to it - and we do it: due diligence, contractual agreements, firewalls, ...  We demand confidentiality of our staff, collaborators, and subcontractors - at a zero tolerance level.  Though we may disclose the corporate names of our clients, we will not disclose the nature of the work -- unless so authorized by you or if it is in the public domain (the examples of past work on this website are drawn from the principals' careers in consulting and science and are in the public domain).
Top of Page   Top of Section

At MATRIX45, we continuously stay abreast on advances in healthcare research and the various client sectors we serve.  We are a learning organization.

In 2005, we are launching a "White Paper" program focused on the various client sectors that we serve.  Each white paper will analyze trends and developments in our client sectors and how they may impact on, or benefit from, an evidence-based approach. 

The first White Paper, currently in progress, aims to bring structure and strategic direction to the post-marketing phase 4 and phase 5 period of a drug's lifecycle.  It is based on a senior management seminar we have been asked to give several times now - and the time is ripe to bundle the ideas for the benefit of the biopharma industry at large.

Every White Paper release will be announced in our News section and published in our Publications section. 

Top of Page   Top of Section

A client's decision to work with companies like ours is an investment and puts capital at risk.  Clients may be reluctant to work with a small and/or young organization.  We owe you the necessary assurances about MATRIX45.

Transparency is a mandate to us, not a desired principle.  Our estimates and accounts are open.  We work with each client on developing mutually acceptable project accounting methods.  We answer all questions - with due confidentiality provisions.

At MATRIX45, we believe we have a responsibility to helping our clients estimate the value and returns on their project commitments.  Return-on-investment calculations may be helpful, but only if they are based on mutually shared assumptions and models.  We would be glad to work with your finance team to develop ROI models.

Especially to our biopharma, diagnostics, and medical device clients, we offer metrics for studies that examine "real world" use of drugs and devices and the associated outcomes.  We can estimate returns under different assumptions of scope, cost, and patient compliance - again, in collaboration with your finance team.

Literally and figuratively, we want to earn our clients' trust.

Top of Page   Top of Section